Literature DB >> 1825506

CD8+ T cell response to Mls-1a determinants involves major histocompatibility complex class II molecules.

Y Chvatchko1, H R MacDonald.   

Abstract

Recent studies indicate that both CD4+ and CD8+ T lymphocytes proliferate in vitro in response to Mls-1a-encoded determinants. Using both immunogenetic and antibody blocking approaches we show here that Mls-1a responses of both subsets require expression of major histocompatibility complex (MHC) class II molecules (I-A and/or I-E) by the stimulator cells. Furthermore, CD8+ T cell responses to Mls-1a/class II MHC do not require (and are in fact inhibited by) the presence of functional CD8 molecules. Taken together, our data underscore the dramatic differences between CD8+ T cell responses to conventional peptide antigens as opposed to "superantigens" such as Mls-1a.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1825506      PMCID: PMC2118829          DOI: 10.1084/jem.173.3.779

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  11 in total

Review 1.  The biologic roles of CD2, CD4, and CD8 in T-cell activation.

Authors:  B E Bierer; B P Sleckman; S E Ratnofsky; S J Burakoff
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

Review 2.  T-cell responses to Mls and to bacterial proteins that mimic its behavior.

Authors:  C A Janeway; J Yagi; P J Conrad; M E Katz; B Jones; S Vroegop; S Buxser
Journal:  Immunol Rev       Date:  1989-02       Impact factor: 12.988

3.  Activation of MHC class I-restricted CD8+ CTL by microbial T cell mitogens. Dependence upon MHC class II expression of the target cells and V beta usage of the responder T cells.

Authors:  T Herrmann; J L Maryanski; P Romero; B Fleischer; H R MacDonald
Journal:  J Immunol       Date:  1990-02-15       Impact factor: 5.422

Review 4.  Immunogenetic and biological aspects of in vitro lymphocyte allotransformation (MLR) in the mouse.

Authors:  H Festenstein
Journal:  Transplant Rev       Date:  1973

5.  BALB.D2-Mlsa--a new congenic mouse strain.

Authors:  H Festenstein; L Berumen
Journal:  Transplantation       Date:  1984-03       Impact factor: 4.939

6.  A third T-cell receptor beta-chain variable region gene encodes reactivity to Mls-1a gene products.

Authors:  M P Happ; D L Woodland; E Palmer
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

7.  Analysis of T cell receptor V beta gene usage in primary mixed lymphocyte reactions: evidence for directive usage by different antigen-presenting cells and Mls-like determinants on T cell blasts.

Authors:  E L Larsson-Sciard; A L Spetz-Hagberg; A Casrouge; P Kourilsky
Journal:  Eur J Immunol       Date:  1990-06       Impact factor: 5.532

8.  CD8+ T cells respond clonally to Mls-1a-encoded determinants.

Authors:  H R MacDonald; R K Lees; Y Chvatchko
Journal:  J Exp Med       Date:  1990-04-01       Impact factor: 14.307

9.  Inhibition of MHC class II-restricted T cell response by Lyt-2 alloantigen.

Authors:  O Kanagawa; R Maki
Journal:  J Exp Med       Date:  1989-09-01       Impact factor: 14.307

10.  Response of mature unprimed CD8+ T cells to Mlsa determinants.

Authors:  S R Webb; J Sprent
Journal:  J Exp Med       Date:  1990-03-01       Impact factor: 14.307

View more
  3 in total

Review 1.  Intestinal Immune System and Amplification of Mouse Mammary Tumor Virus.

Authors:  Lankai Chen; Xipeng Zhang; Guisheng Liu; Shuo Chen; Minying Zheng; Siwei Zhu; Shiwu Zhang
Journal:  Front Cell Infect Microbiol       Date:  2022-01-13       Impact factor: 5.293

2.  CD4 expression is differentially required for deletion of MLS-1a-reactive T cells.

Authors:  V A Wallace; A Rahemtulla; E Timms; J Penninger; T W Mak
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307

3.  Toxoplasma gondii possesses a superantigen activity that selectively expands murine T cell receptor V beta 5-bearing CD8+ lymphocytes.

Authors:  E Y Denkers; P Caspar; A Sher
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.